[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"congestive-heart-failurechf\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:congestive-heart-failurechf":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,71,95,123,139,162,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053827","evaluating-the-use-of-prehospital-lung-ultrasound-in-ems-a-multicenter-pilot-study-100053827",false,"NCT07549334","Evaluating the Use of Prehospital Lung Ultrasound in EMS: A Multicenter Pilot Study","Inclusion Criteria:\n\n* Patient treated by Emergency Medical Services\n* Complaint of dyspnea\n\nAt least one of the following:\n\n* Oxygen saturation \\\u003C94% on room air\n* Abnormal lung sounds\n* Increased work of breathing\n* Pedal edema\n* Orthopnea\n\nExclusion Criteria:\n\n* Pediatric patients (\\\u003C18)\n* Traumatic etiology\n* Cardiac arrest at any point prehospitally\n* No ultrasound-trained paramedic involved in patient's care","ALL","18 Years",{"count":18,"type":19},1000,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this prospective nonrandomized study is to determine if prehospital lung ultrasound findings result in a change in patient management. This study will look at how lung ultrasound exam improves diagnosis of respiratory distress in patients being treated by Emergency Medical Services, such as patients with heart failure. Additional questions include:\n\n* How well can paramedics obtain and interpret ultrasound images?\n* How does ultrasound use change treatment received by patients?\n* How does ultrasound use impact patient outcomes? Participants will receive a lung ultrasound exam, but otherwise receive standard evaluation and care. Patients who receive ultrasound will be compared to those who did not receive ultrasound for logistical reasons and patients from before the use of ultrasound. Ultrasound will not be withheld from any patient for the purposes of the study.",[25,26],"Congestive Heart Failure(CHF)","Pulmonary Edema",[28,29,30,26,31,32],"Ultrasound","Emergency Medical Services","Pulmonary Ultrasound","Congestive Heart Failure","Paramedic","NOT_YET_RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":19},"2026-08",{"date":41,"type":19},"2028-12",{"name":43,"class":44},"Rutgers, The State University of New Jersey","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100620378","palliative-care-for-people-with-hf-100620378","NCT07356843","Palliative Care for People With HF","Implementing Community Palliative Care for People With Heart Failure","Inclusion Criteria:\n\n* Outpatient clinician or staff member (e.g. physician, physician assistant, nurse practitioner, registered nurse, social worker, psychologist, medical assistant) or healthcare leadership personnel (e.g. Chief Nursing Officer, Clinic Medical Director etc.)\n* at least 6 months of experience caring for patients with HF\n* 18 years or older\n\nExclusion Criteria:\n\n\\-",{"count":54,"type":19},20,"OBSERVATIONAL","Imagine having heart failure, a condition where the heart struggles to pump blood, making daily life hard. People with heart failure often don't feel well and end up going to the hospital a lot. Many of these people could feel better with extra help, but there aren't many programs that offer support beyond usual heart failure treatments. That's where the ADAPT program comes in, which stands for \"Advancing Symptom Alleviation with Palliative Treatment.\" In this program, nurses and social workers call people weekly, helping them manage their toughest symptoms, offering tools to cope with heart failure, and keeping the patients' current doctors involved. We tested this program in a research study with heart failure patients and found that it improved their quality of life and lowered depression, anxiety, and heart failure symptoms. The question now is if the ADAPT program will work in the community, outside of a research setting, so that more people could benefit from it. Specifically, can the ADAPT program work well in new places? Will patients and their families find it helpful? Most importantly, can it help improve the lives of people with heart failure in these new settings? To answer these questions, the study team will work with healthcare providers to 1) ask how to adjust the ADAPT program to work well in various settings (e.g. primary care, heart failure clinic) and 2) use this information to create simple materials and trainings to help them easily provide ADAPT. This will prepare for the next phase of this project to test out the new ADAPT program.",[31,25,58,59],"Congestive Heart Failure (CHF)","Congestive Heart Failure Chronic","RECRUITING","2026-06-15",{"date":63,"type":37},"2026-06-16",{"date":65,"type":37},"2025-10-29",{"date":67,"type":19},"2028-09",{"name":69,"class":44},"Indiana University",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":20,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":70},"100641862","biomarker-based-diagnostic-toolkit-to-personalise-pharmacological-approaches-in-congestive-heart-failure-the-biotool-chf-validation-trial-100641862","NCT07635810","BIOmarker Based Diagnostic TOOLkit to Personalise Pharmacological Approaches in Congestive Heart Failure: the BIOTOOL-CHF Validation Trial","Inclusion criteria:\n\n1. Adult patients with symptomatic chronic heart failure diagnosed at least 3 months prior to randomization\n2. Treatment with at least 40 mg of oral furosemide or equivalent at the time of enrolment to control symptoms\n3. At least one of the following:\n\n   * At discharge from hospitalization for heart failure\n   * History of hospitalization for heart failure in the previous 3 months\n   * History of treatment with intravenous diuretics or inotropes in ambulatory setting in the previous 3 months\n   * B-type Natriuretic Peptide (BNP) \\> 400 pg\u002Fml or N-terminal pro-B-type natriuretic peptide (NT-proBNP) \\> 1000 pg\u002Fml if in sinus rhythm or BNP \\> 800 pg\u002Fml or NT-proBNP \\> 2000 pg\u002Fml if in atrial fibrillation (AF) assessed within 4 weeks before enrolment\n\nExclusion criteria:\n\n1. Acute coronary syndrome or cerebrovascular accident in the previous 30 days\n2. Acute heart failure requiring immediate hospitalization or intravenous therapy (acute pulmonary edema, cardiogenic shock, arrhythmic storm)\n3. Clinical congestion score greater or equal to 5 at the time of randomization\n4. Any cardiovascular intervention (cardiac surgery\u002Fcoronary revascularization (Coronary Artery Bypass Grafting (CABG) or Percutaneous Coronary Intervention (PCI))\u002F Cardiac Resynchronization Therapy (CRT) implant, percutaneous treatment of valve disease, arrhythmias ablation) performed in the previous 3 months or planned in the following 3 months\n5. Active myocarditis\n6. Patients with any wearable or implantable device for congestion monitoring which is actively used to guide clinical practice\n7. Patients with left ventricular assist device (LVAD)\u002F biventricular assist device (Bi-VAD) or heart transplantation\n8. Severe stenotic valvular disease\n9. Glomerular Filtration Rate (GFR) \\\u003C15 ml\u002Fmin (estimated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)) or dialysis (hemodialysis or peritoneal dialysis)\n10. Liver cirrhosis with ascites\n11. Significant cognitive impairment\n12. Pregnancy or planned pregnancy during the study period\n13. Active malignancy or severe hematological disorders",{"count":78,"type":19},600,[22],"By the re-analysis, in the BIOTOOL-CHF DISCO study, of a previously enrolled cohort of patients, a Biological Congestion Score (BCS) was newly developed. The BCS integrates four congestion-related biomarkers with key clinical variables. The BIOTOOL-CHF VALID trial is designed to prospectively evaluate whether a BCS-assisted strategy for diuretic management improves clinical outcomes and quality of life in patients with chronic Heart Failure (HF) compared with standard care.",[25],[83,84,85],"Congestion","Biomarkers","Heart failure","2026-06-10",{"date":88,"type":37},"2026-06-12",{"date":90,"type":19},"2026-07-15",{"date":92,"type":19},"2028-12-04",{"name":94,"class":44},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":70},"100625186","drain-drainage-in-acute-decompensated-heart-failure-with-pleural-effusions-100625186","NCT07419360","DRAIN: DRainage in Acute Decompensated Heart faIlure With Pleural effusioNs","Role of Therapeutic Thoracentesis in Hospitalized Patients With Acute Decompensated Heart Failure: Randomized Controlled Trial","DRAIN-IT","Inclusion Criteria:\n\n* Adult patients age \\>18 years and.\n* Clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload (e.g., peripheral edema, pleural effusion, or ascites) and\n* Assessment of left ventricular ejection fraction (LVEF) by echocardiography performed during the time of index hospitalization or within 3 months prior to enrollment and\n* Serum NT-proBNP level of \\>1000 pg\u002Fml or Serum BNP\\>250 pg\u002Fml at the time of enrollment and\n* Radiographic evidence of moderate to large pleural effusion, defined as pleural fluid occupying more than 1\u002F3rd of the hemithorax on chest X-ray.\n\nExclusion Criteria:\n\n* Clinical indication for diagnostic thoracentesis - Presence of fever, clinical signs of infection, or atypical pleural effusion for CHF (unilateral left-sided effusion, findings suggestive of malignancy, infection, or alternative etiologies) or.\n* Loculated pleural effusion - Evidence of loculated pleural effusion on thoracic ultrasound, as defined as the presence of septations or complex homogenous echogenic fluid (see Imaging Assessment section) or.\n* Clinical indication for therapeutic thoracentesis - Presence of massive pleural effusion with acute respiratory failure requiring positive pressure ventilation, high-flow oxygen therapy (\\>15 liters per minute of flow), or tension hydrothorax (massive effusion with mediastinal shift and hemodynamic compromise) or.\n* Contraindication to thoracentesis, uncontrolled bleeding diathesis, or irreversible INR \\> 2.0 and platelet count \\\u003C50,000 or.\n* Patient with mechanical mitral valve, where anticoagulation cannot be safely held or.\n* Pleural procedure, such as but not limited to thoracentesis, chest tube placement, or thoracoscopy, within 3 months prior to enrollment or.\n* Cardiac or thoracic surgery within 3 months prior to enrollment or.\n* Requirement for chronic renal replacement therapy, such as hemodialysis or peritoneal dialysis or.\n* Pregnancy or\n* Inability or unwillingness to provide informed consent, or current incarceration (prisoners).",{"count":104,"type":19},216,[22],"The goal of this study is to assess if removal of fluid around the lungs (pleural effusion) by a routine procedure called as thoracentesis is helpful to decrease shortness of breath in hospitalized patients with congestive heart failure and have pleural effusion.\n\nResearchers will compare thoracentesis with medical therapy to medical therapy alone to see if one treatment is superior to the other treatment in relieving shortness of breath.\n\nParticipants will :\n\n1. Receive medical therapy with or without thoracentesis\n2. Record degree of shortness of breath and quality of life before and after the intervention using predefined standard scales.\n3. Telephonic call for 15- 30 mins at day 14 and 30 after enrollment to assess shortness of breath and quality of life",[25,108],"Pleural Effusion Due to Congestive Heart Failure",[110,111,112,113],"congestive heart failure","pleural effusion","dyspnea","hospital length of stay","2026-04-24",{"date":116,"type":37},"2026-04-30",{"date":118,"type":37},"2026-02-15",{"date":120,"type":19},"2029-06",{"name":122,"class":44},"Albany Medical College",{"id":124,"slug":4,"hasResults":11,"nctId":12,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":20,"phases":128,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":45},"100635180","Evaluating the Feasibility of Prehospital Lung Ultrasound","Evaluating the Feasibility of Prehospital Lung Ultrasound: A Multicenter Pilot Study",{"count":18,"type":19},[22],"The goal of this prospective nonrandomized study is to determine if a lung ultrasound exam improves diagnosis of respiratory distress in patients being treated by Emergency Medical Services. The main question it aims to answer is whether ultrasound use increases likelihood of correctly diagnosing heart failure. Additional questions include:\n\n* How well can paramedics obtain and interpret ultrasound images?\n* How does ultrasound use change treatment received by patients?\n* How does ultrasound use impact patient outcomes? Participants will receive a lung ultrasound exam, but otherwise receive standard evaluation and care. Patients who receive ultrasound will be compared to those who did not receive ultrasound for logistical reasons and patients from before the use of ultrasound. Ultrasound will not be withheld from any patient for the purposes of the study.",[25,26],[28,29,30,26,31,32],"2026-04-17",{"date":114,"type":37},{"date":135,"type":19},"2026-04",{"date":137,"type":19},"2028-04",{"name":43,"class":44},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":70},"100610232","observational-study-of-patients-undergoing-diagnostic-right-heart-catheterization-100610232","NCT07224906","Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization","Observational Study of the HemoCept Device During Right Heart Catheterization at Boulder Heart","Inclusion Criteria:\n\n* Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures.\n* Subjects can be any gender but must be age 18 or older.\n* Subject is able and willing to provide informed consent and HIPAA authorization.\n* Subject is able and willing to meet all study requirements.\n* Scheduled for a diagnostic right heart catheterization (RHC-only or combined RHC+LHC; left-heart-only procedures are not eligible)\n\nExclusion Criteria:\n\n* Subject is pregnant, breastfeeding, or intends to become pregnant during this study.",{"count":147,"type":19},50,"The objective of this observational pilot study is to collect HemoCept device data from subjects undergoing diagnostic right heart catheterization (RHC) procedures.",[150,25,151],"Pulmonary Hypertension","Valve Disease, Heart","2026-04-09",{"date":154,"type":37},"2026-04-13",{"date":156,"type":37},"2025-12-01",{"date":158,"type":19},"2027-01",{"name":160,"class":161},"HemoCept Inc.","INDUSTRY",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":168,"minAge":16,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":20,"phases":171,"briefSummary":172,"conditions":173,"keywords":178,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":45},"100564422","social-prescribing-to-improve-adherence-and-outcomes-in-women-with-heart-failure-100564422","NCT06628973","Social Prescribing to Improve Adherence and Outcomes in Women With Heart Failure","Inclusion Criteria:\n\n* Women\n* 18 years of age or older\n* Documented HF of any etiology\n* Valid personal health identifier\n* Two or more points on the weighted SPARK questionnaire\n\nExclusion Criteria:\n\n* Patients not meeting inclusion criteria\n* Do not take HF medications\n* Not residents of the province where they are being followed or who have opted out from their provincial health registry\n* Patients with severe cognitive impairment or other conditions that significantly impact the ability to participate in SP will also be excluded.","FEMALE",{"count":170,"type":19},200,[22],"Background: Heart Failure (HF) is the second most common cause of hospitalizations for women in North America. Non-adherence to guideline-directed medical therapy (GDMT) is associated with 50% of all treatment failures and high rates of hospitalizations and death. A recent Canadian study showed that adherence to three or more GDMT medications occurred in only 20% of Canadian HF patients. Despite clear guidelines on the pharmacologic management of HF and the introduction of new and effective drugs, adherence to GDMT in women with HF is low. Furthermore, the rates of hospitalizations have not improved in Canada over the last decade, and mortality in Canadian women with HF remains high. One explanation may be that social determinants of health (SDOH), which are known to be strong predictors of both adherence and adverse outcomes in HF, have not specifically been targeted to improve either adherence or outcomes in HF. Social prescribing (SP) is an innovative, non-medical intervention that aims to improve health by addressing SDOH. However, whether using SP to LINK clinical and social services for the benefit of socially vulnerable HF women can improve outcome is unknown. By targeting SDOH, which are strong predictors of adherence and outcomes in HF, and which have been shown to disproportionately disfavor women, SP has the potential to significantly improve medication adherence, quality of life and outcomes in women with HF.\n\nObjectives: The overall aim of this study is to assess whether SP, through individualized, SDOH-targeted interventions, can improve adherence and quality of life in Canadian women with HF and at high risk for no adherence. Primary objective: To determine whether SP can improve adherence to GDMT. Secondary objective: To determine whether SP can improve quality of life.\n\nMethods: This is an intention to treat, multicenter (five centers), and open-labeled, randomized clinical trial. Women with HF with two or more points on a weighted SDOH questionnaire (SPARK tool) will be randomly assigned to either SP or control group. Women in the SP group will meet with a link worker (LW) who will perform SP. SP will consist of personalized referrals to non-medical supports or services based on women's specific SDOH-related vulnerabilities and social needs. SP will address social needs such as issues with income, unemployment, transportation, mobility, dependents, housing, loneliness, mental health, health literacy, medication management and medical appointment schedules. Social prescriptions will be based on the interview conducted by the LW and will prioritize SDOH-related vulnerabilities identified on the SPARK questionnaire. Participants in the control group will receive standard care as is typically offered in the current specialized HF clinic in the participating centers. Controls will not meet with a LW, but, as usual, their physician or treating team may refer them to any specialists or services deemed necessary.\n\nOutcome measures: The primary outcome will be adherence to GDMT measured with PDC obtained from provincial administrative databases and the secondary outcome will be quality of life measures including physical limitations, social limitations, as measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12).\n\nSample size Calculations: The sample size was calculated using the primary outcome of adherence to GDMT measured with PDC as a continuous variable. In one observational study on adherence to HF medications which compared women and males adherence using PDCs, adherence in women was 63% with a SD of 23%. The impact of an absolute increase of 10% in PDC on clinical end points was considered significant. Using an alpha of 0.05 and a power of 0.80, a minimum of 166 participants would be needed to detect a statistically significant difference. Based on pilot data, the proportion of women followed in heart failure clinics is 28% and the proportion of eligible women (i.e. 1 point or more on the SPARK questionnaire) is about 30%. Considering a 30% refusal rate and a 5% dropout rate (intention to treat with registry based outcome), the five chosen centers should totalize 188 participants. The secondary outcome, the KCCQ, is a continuous variable for which a change of five points or more (5%) is considered clinically significant. Using an alpha of 0.05 and a power of 0.80, 126 patients would be required to detect such a difference.\n\nSignificance: SP holds immense potential for women with HF by addressing critical gaps in care. SP may help bridge the gap between healthcare providers and community resources, providing tailored support addressing SDOH that disproportionately affect women with HF. SP has the potential to significantly enhance adherence to GDMT, which has been shown to greatly, reduce hospitalizations and mortality in this vulnerable population.",[174,175,176,25,177],"Heart Failure","Cardiac Failure","Heart Decompensation","Myocardial Failure",[174,179,180,181,182,183,184,185,186,31,187],"Social Determinants of Health","Adherence","Social Prescribing","Hospitalizations","Readmissions","Sex","Gender","Quality of Life","Women","2026-02-18",{"date":190,"type":37},"2026-02-20",{"date":192,"type":37},"2025-10-23",{"date":194,"type":19},"2028-12-31",{"name":196,"class":44},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":70},"100592422","evaluating-residual-congestion-at-discharge-in-acute-heart-failure-patients-100592422","NCT06993220","Evaluating Residual Congestion at Discharge in Acute Heart Failure Patients","Multiparametric Assessment of Residual Congestion at Discharge in Patients With Acute Heart Failure","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Patients hospitalized for new onset heart failure or worsening heart failure defined by:\n\n  1. Symptoms classified as New York Heart Association class III or IV.\n  2. Clinical or instrumental signs of volume overload (e.g., dyspnea with evidence of pulmonary congestion on X-rays or lung ultrasound, pitting edema, and jugular venous distension).\n  3. Elevated NT-proBNP levels within the first 24 hours of admission (cutoff values: 450 ng\u002FL for patients \\\u003C 50 years; \\>900 ng\u002FL for patients aged 50-75 years; \\>1800 ng\u002FL for patients \\>75 years).\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Known diagnosis of septicemia.\n* Glomerular filtration rate \\\u003C 15 ml\u002Fmin.\n* Life expectancy \\\u003C 6 months.\n* Active myocarditis.\n* Heart transplant recipients.\n* Patients with ventricular assist devices.\n* Congenital heart diseases.\n* Moderate-to-severe liver disease (Child-Pugh B-C).\n* Patients that will not be followed up by the Heart Failure Unit.",{"count":205,"type":19},500,"Treatment of congestion is one of the main goals in patients hospitalized for acute heart failure. Nevertheless, current evidence shows that decongestion is often not achieved and that residual congestion at discharge is strongly associated with poor outcomes. While this association has been demonstrated, previous studies have primarily focused on single parameters of congestion (physical examination, biomarkers, or imaging features). The aim of the study is to assess residual congestion at discharge using a multiparametric approach and to compare the prognostic value of each evaluation strategy. Additionally, the analysis will be supported by artificial intelligence to develop a multiparametric prognostic algorithm that can provide an improved predictive model compared to standard statistical approaches.",[208,25],"Acute Heart Failure (AHF)",[210,211,212,213],"acute heart failure","residual congestion","multiparametric assessment","risk stratification","2025-07-15",{"date":216,"type":37},"2025-07-18",{"date":218,"type":37},"2025-01-01",{"date":220,"type":19},"2027-01-01",{"name":222,"class":44},"Consorci Sanitari Integral"]